Letronat Tablet contains Letrozole 2.5 mg, a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. By inhibiting the aromatase enzyme, Letrozole effectively reduces estrogen production, thereby limiting the growth of estrogen-dependent tumors. Letronat is indicated for adjuvant treatment of early-stage breast cancer, as well as for advanced or metastatic breast cancer where hormone therapy is appropriate. The tablet is typically administered once daily, with or without food, as prescribed by a healthcare professional. Letrozole’s efficacy in reducing tumor size and delaying disease progression has been well-documented in clinical trials. Common adverse effects may include hot flashes, fatigue, arthralgia, and increased sweating, while less frequent but serious side effects can involve bone density reduction and cardiovascular events, necessitating regular monitoring. Letronat should be used with caution in patients with hepatic impairment and is contraindicated during pregnancy due to potential teratogenic effects. Patients are advised to inform their physician of any pre-existing conditions or concomitant medications to avoid interactions. Letronat Tablet is a critical component in the management of hormone-sensitive breast cancer, contributing to improved patient outcomes and quality of life.